secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sanara MedTech Inc. (SMTI)
CIK:        0000714256
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001493152-23-040572
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sanara MedTech Q3 revenue $16M (record), net loss narrows to $1.1M, Adj. EBITDA positive $0.3M
--------------------------------------------------------------------------------

- Q3 net revenue $16.0M, up 23% YoY; net loss $1.1M vs $1.5M loss a year ago.
- Adjusted EBITDA positive $0.3M vs negative $1.6M in Q3 2022.
- Acquired certain collagen assets (CellerateRX, HYCOL) in August, eliminating future royalties.
- First sales of ALLOCYTE Plus and BIASURGE completed post-quarter; supply issues for ALLOCYTE resolved.
- Twelve new sales reps hired in 9M 2023; products sold in over 1,000 facilities across 32 states.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/714256/000149315223040572/0001493152-23-040572-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/714256/000149315223040572/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-040572

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer